IBJNews

Lilly wins court ban on generic copy of Gemzar

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version of the cancer drug Gemzar until November.

U.S. District Judge Sarah Evans Barker in Indianapolis, where Lilly is based, rejected Teva’s claims that the patent was invalid and unenforceable. The drug, approved by regulators in 1996, generated $1.36 billion in sales last year.

The ruling gives Lilly time to pursue an appeal over a second patent that expires in 2013. A federal judge in Michigan, in a case involving generic-drug maker Sun Pharmaceutical Industries Ltd., last year said the second patent was invalid. Arguments before an appeals court in Washington, D.C., are scheduled for May.

Teva, the world’s biggest generic-drug maker, also was challenging the invalidity of the latter patent. Barker ruled that Lilly can’t assert the 2013 patent against Petah Tikva, Israel-based Teva because of the earlier ruling in Michigan.

Teva said Thursday in an e-mailed statement that it believes it was first to challenge the 2010 patent and thus will be able to introduce a generic version of the drug without any other competition for 180 days when the patent expires.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
thisissue1-092914.jpg 092914

Subscribe to IBJ
ADVERTISEMENT